HK Stock Market Move | MEDBOT-B(02252) rose by over 5%. The commercialization process of Tuomai has entered a comprehensive acceleration phase, with overseas orders exceeding 60 units.

MEDBOT-B (02252) rose by over 5%, as of the time of writing, it was up by 5.01% at HK$30.2, with a turnover of HK$130 million. On the news front, on October 8, MEDBOT-B issued an announcement stating that, according to preliminary internal statistics of the group, as of the date of the announcement, the total comprehensive order quantity of the group's endoscope, orthopedics, and vascular intervention core products has exceeded 170 units. Among them, the core product TMM endoscope surgery Siasun Robot & Automation (TMM) has accumulated over one hundred commercial orders worldwide. TMM has been installed in nearly 80 units globally, ranking first among domestic brands, and its commercialization process has entered a phase of comprehensive acceleration. As the first domestically produced endoscope surgery to enter the overseas market, TMM's overseas orders have surpassed 60 units, with installations covering nearly 40 countries and regions in Asia, Europe, Africa, Oceania, and South America. It has carried out large-scale clinical surgeries in mainstream hospital systems in Italy, Belgium, India, Brazil, Argentina, the UAE, and dozens of other countries. Recently, the group's commercial layout in the global high-end medical market has once again achieved a milestone breakthrough as TMM has successfully completed the commercial deployment of single-hole and multi-hole series in a top two global medical institution, realizing the implementation of a combined intelligent surgical solution.